Sentynl Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZYCUBO® (copper histidinate) for the treatment of patients with Menkes disease, a rare, inherited disorder that affects copper absorption and distribution in the body.

Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the United States, following approval from the U.S. Food and Drug Administration (USFDA). The product is the generic equivalent of Extra-Strength Pataday® (of Novartis AG) Once-Daily Relief, a leading over-the-counter antihistamine eye drop.